DNMT1 and prostate carcinoma: Silibinin, the major active constituent of the silymarin, induced epigenetic alterations in human prostate cancer cells that involve an increase in the activity of total DNA methyltransferase (DNMT) while decreasing expression levels of histone deacetylases 1-2 (HDACs1-2) [106].